Sari la conținut

Română · beta. Traducerea a fost făcută automat și este încă în curs de revizuire. Citește pagina în engleză

perspectiva aiqbenchCercetare AI

analiza aiqbench

EpiGuard applies an LLM-style agent to infectious-disease forecasting, with the notable ideas being regime-adaptive analysis across data-sparse and data-rich settings and reusable standard operating procedures that carry over to unseen diseases. The reported gains of 9.68% and 14.04% over forecasting baselines are self-reported on two CDC datasets, so readers should check which baselines were used and whether the results hold under independent evaluation. The core question for AI readers is whether the "self-improving" SOP mechanism generalizes beyond the evaluated diseases and regions.
Sursă care acoperăarXiv
Ce este aceastaLectura unui model asupra articolului și a acoperirii conexe, scrisă pentru aiqbench. Nu sunt cuvintele publicației.

EpiGuard: An Autonomous Infectious-Disease Early Warning Agent Platform

arXiv3 min de cititArticolul și perspectiva sunt în engleză.

arXiv:2610.19396v1 Announce Type: new Abstract: Infectious disease outbreaks often spread rapidly before signs of widespread transmission become apparent, leaving a big challenge for rapid response and effective intervention. However, current infectious-disease early-warning systems face three major challenges: fragmented epidemiological evidence across diverse surveillance sources, highly uneven data availability across diseases and geographic regions, and delayed warning procedure caused by manual data collection, analysis, and reporting. To address these challenges, we present EpiGuard, an autonomous, continually self-improving agentic platform for timely and reliable early warning of more than 50 infectious diseases across different regions. EpiGuard proactively monitors and captures newly released official surveillance records, using the latest available evidence for risk assessments. It dynamically adjusts its analytical strategy across three evidence availability regimes, enabling reliable risk assessment under diverse data conditions, ranging from the absence of historical observations to sparse and abundant evidence. Moreover, EpiGuard learns from the successful execution process by preserving effective data-acquisition and analytical procedures as reusable standard operating procedures, enabling it to progressively generalize to previously unseen diseases and regions. We use officially released infectious-disease surveillance data from the China CDC and the United States CDC to evaluate EpiGuard's effectiveness. Experimental results demonstrate that EpiGuard outperforms state-of-the-art forecasting systems, improving forecasting performance by 9.68% and 14.04% on the China CDC and U.S. CDC datasets, respectively.

Abstract:Infectious disease outbreaks often spread rapidly before signs of widespread transmission become apparent, leaving a big challenge for rapid response and effective intervention. However, current infectious-disease early-warning systems face three major challenges: fragmented epidemiological evidence across diverse surveillance sources, highly uneven data availability across diseases and geographic regions, and delayed warning procedure caused by manual data collection, analysis, and reporting. To address these challenges, we present EpiGuard, an autonomous, continually self-improving agentic platform for timely and reliable early warning of more than 50 infectious diseases across different regions. EpiGuard proactively monitors and captures newly released official surveillance records, using the latest available evidence for risk assessments. It dynamically adjusts its analytical strategy across three evidence availability regimes, enabling reliable risk assessment under diverse data conditions, ranging from the absence of historical observations to sparse and abundant evidence. Moreover, EpiGuard learns from the successful execution process by preserving effective data-acquisition and analytical procedures as reusable standard operating procedures, enabling it to progressively generalize to previously unseen diseases and regions. We use officially released infectious-disease surveillance data from the China CDC and the United States CDC to evaluate EpiGuard's effectiveness. Experimental results demonstrate that EpiGuard outperforms state-of-the-art forecasting systems, improving forecasting performance by 9.68% and 14.04% on the China CDC and U.S. CDC datasets, respectively.

Artificial Intelligence (cs.AI)

arXiv:2610.19396 [cs.AI]

(or arXiv:2610.19396v1 [cs.AI] for this version)

https://doi.org/10.48550/arXiv.2610.19396 Focus to learn more arXiv-issued DOI via DataCite (pending registration)

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Text integral sub licența deschisă a publicației · 307 cuvinte

Subiecte conexe